PRL and type 2 diabetes mellitus: Although prolactin did not reliably reflect cardiometabolic risk in an analysis of 3232 subjects from the Framingham Heart Study [47], a recent study of 10,907 patients with type 2 diabetes showed a positive association of serum prolactin with mortality [48], and a recent meta-analysis of 14 studies involving 23,596 patients confirmed that serum prolactin is an independent predictor of all-cause mortality and cardiovascular mortality [49].